NEWARK, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate, ...
NEWARK, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN),. (“Rain”), a late-stage company developing precision oncology therapeutics, today reports financial results ...
SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Rain Oncology Inc. (NASDAQ: ...
Rain Therapeutics RAIN has completed patient enrolment in its Phase 3 MANTRA trial of its lead asset, milademetan for well-differentiated / dedifferentiated (WD/DD) liposarcoma (LPS). The MANTRA study ...
NEW YORK, July 17, 2023 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of ...
NEWARK, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a clinical-stage company developing precision oncology therapeutics, today announced that the first patient has been ...
- The Phase 3 MANTRA trial did not meet the primary endpoint of progression free survival vs. standard of care - - The median PFS was 3.6 months for milademetan versus 2.2 months for trabectedin with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results